Clinical Trials
27 trialsNCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
NCT01253161 2023-03-06
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02215070 2021-11-17
Pasireotide in Prevention of GI Toxicity
Duke University
Phase 2 Completed
NCT01563354 2021-04-02
LUNA
Novartis
Phase 2 Completed
NCT01468532 2021-03-25
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT01270321 2021-02-17
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Emory University
Phase 2 Completed
NCT00446082 2020-12-21
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Novartis
Phase 1 Completed
NCT01364415 2020-12-21
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Novartis
Phase 1 Completed
NCT01646684 2020-12-21
Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer
Novartis
Phase 1 Completed
NCT01385956 2020-09-28
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02354508 2019-12-10
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Novartis
Phase 3 Completed
NCT01673646 2019-09-16
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Novartis
Phase 2 Completed
NCT01590199 2019-04-16
MACS2002
Novartis
Phase 1 Completed
NCT01469572 2018-10-18
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Emory University
Phase 1 Completed
NCT01137682 2018-04-05
PAOLA
Novartis
Phase 3 Completed
NCT02021942 2018-02-05
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
University of Regensburg
Phase 2 Completed
NCT01252251 2017-08-01
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01639352 2017-07-12
Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Completed
NCT01356862 2017-01-25
SOM 230
Alliance Pour La Recherche en Cancerologie
Phase 2 Completed
NCT01372644 2016-12-05
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
NYU Langone Health
Phase 1 Completed
NCT00804336 2016-10-19
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01620138 2016-08-22
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
Universidade Federal do Rio de Janeiro
Phase 2/3 Completed
NCT01625520 2016-04-25
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
Federico II University
Phase 2 Completed
NCT01488487 2016-04-07
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00994110 2016-02-01
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT00690430 2013-07-30
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Novartis
Phase 3 Completed
NCT00088595 2012-06-04
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Novartis
Phase 2 Completed